Skip to content
Biotechnology

With an Eye on the Future, Biolog Launches Odin

Biolog, Inc. 2 mins read

HAYWARD, CA / ACCESSWIRE / June 15, 2023 / Biolog, Inc., a leading provider of microbial polyphasic analysis, today announced the launch of the Odin™ system, an all-in-one cellular phenotyping and microbial identification platform. Odin is compatible with all Biolog assays and is available now.

Until today, Biolog's OmniLog® platform was the gold standard for researchers who want actionable insights on microbial metabolic phenotypes. Odin now builds on that foundation while maintaining the core capabilities to incubate, analyze, and compare thousands of microbial and mammalian growth conditions in a single experiment, and to identify aerobic bacteria by its metabolic fingerprint.

Odin changes up the detection method and uses Optical Density (OD), which enables a critical additional modality to measure cell growth. Now on a single platform, researchers can distinguish the effect of a substrate on growth (by OD) and by respiration using our proprietary dye, now an absorbance-based measurement. With the additional Odin capabilities, researchers can now decouple a microbe's respiration rate from its division rate and more fully understand the metabolic output of a cell. With a fully loaded system, Odin records the OD for all conditions for up to 50 plates at a time, measuring the kinetics of cell growth and respiration for thousands of conditions in parallel.

Odin also has broader identification capabilities, including anaerobes, yeast, and filamentous fungi. All told, Odin can identify thousands of microbes, allowing researchers to classify unknown organisms and phenotype them on the same platform.

"We heard from our customers the need to directly measure growth. In a short time, we brought in additional scientific expertise, and built a product development engine. The customer-focused mindset and our dedicated teams have enabled us to quickly meet the needs of our customers," said Robert Wicke, CEO of Biolog.

"Understanding how microbes respond to their environment and food sources is the major economic driver in sustainable agriculture, bioprocessing and synthetic biology, to name just a few areas. We are enthusiastic about the foundation that Odin creates for Biolog and our customers," said Mr. Wicke.

About Biolog

Biolog has the tools, services, and support to provide the microbial phenotypic characterization and polyphasic identification capabilities required to produce functionally relevant insights. Our products and services enable characterization of microbial and mammalian cells as well as identification of thousands of species of bacteria, yeast, and fungi. Learn more at www.biolog.com.

Contact Information:

John Proctor, Ph.D.
CCO
[email protected]
(408)306-0414

SOURCE: Biolog Inc.

.


View source version on accesswire.com:
https://www.accesswire.com/761372/With-an-Eye-on-the-Future-Biolog-Launches-Odin

More from this category

  • Biotechnology
  • 22/04/2025
  • 10:41
Moolec Science SA

Moolec Science Enters Into Transformational Transaction Expanding Across Multiple Technology Platforms

LUXEMBOURG, LU / ACCESS Newswire / April 21, 2025 / Moolec Science SA (NASDAQ:MLEC) ("The Company" or "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced that it has entered into a Business Combination Agreement (the "BCA") with Bioceres Group Limited ("Bioceres Group") and other related entities in an all-stock transaction (the "Business Combination").Subject to the terms and conditions of the BCA, which was signed on April 17, 2025, several parties will transfer their respective holdings in Bioceres Group, Nutrecon LLC ("Nutrecon"), and Gentle Technologies Corp ("Gentle Tech", and together with…

  • Biotechnology, Business Company News
  • 10/04/2025
  • 10:55
Jane Morgan Management

ReNerve Expands Global Footprint with Strategic Partnership for Indian Market

Melbourne, Australia – 10 April 2025 | ReNerve Limited (ASX: RNV) (“ReNerve” or the “Company”), an Australian medical device company specialising in peripheral nerve repair technologies, is pleased to announce it has entered into a strategic partnership with NetCentrix Ventures to establish and expand its operations in the Indian healthcare market. This agreement marks a key milestone in ReNerve’s global commercialisation strategy and supports the introduction of its flagship NervAlign® Nerve Cuff into one of the world’s fastest-growing medical device markets. Highlights ReNerve partners with NetCentrix Ventures to secure regulatory approval and drive commercialisation of the NervAlign® Nerve Cuff in…

  • Contains:
  • Biotechnology, Business Company News
  • 09/04/2025
  • 14:39
Optiscan Imaging Limited (ASX:OIL)

Optiscan Imaging (ASX:OIL) Optiscan to Showcase Imaging Tech at Site Tour

During the visit, attendees will receive a detailed overview ofOptiscan’s strategic direction, commercialisation progress, and key milestones across its three core markets: • Medical – advancing real-time digital pathology and precision surgery• Veterinary – expanding imaging capabilities into animal healthcare • Life Sciences – enabling high-resolution live-cell imaging inpreclinical research The visit will include live demonstrations of Optiscan’s expanding product range, including: • InVue™ – a next-generation system for surgical applications • InForm™ – digital pathology technology • InVivage® – an intra-oral endomicroscope • ViewnVivo® – a high-resolution imaging system for real-time life sciences research In addition, Optiscan will provide…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.